Skip to main content

Advertisement

Log in

Neuropsychiatric Effects of Prescription Drug Abuse

  • Published:
Neuropsychology Review Aims and scope Submit manuscript

Abstract

Prescription drugs have become a major category of abused substances, and there is evidence that the prevalence of prescription drug abuse may soon overtake that of illicit drugs. Study of prescription drugs has been hampered by vague terminology, since prescription drugs are only separated from other drugs of abuse by social and legal constructs. Reviewed herein is published literature on the abuse of four major categories of abused prescription drugs: sedative-hypnotics, stimulants, anabolic steroids, and anticholinergics. The review emphasizes evidence regarding the effects of these drugs on neural systems. Other abused prescription drugs that fall outside of the major categories are also briefly addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Abernethy, M. K., & Becker, L. B. (1992). Acute nutmeg intoxication. The American Journal of Emergency Medicine, 10, 429–430.

    Article  PubMed  CAS  Google Scholar 

  • Alen, M., Rahkila, P., Reinila, M., & Vihko, R. (1987). Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. The American Journal of Sports Medicine, 15, 357–361.

    Article  PubMed  CAS  Google Scholar 

  • Alen, M., Reinila, M., & Vihko, R. (1985). Response of serum hormones to androgen administration in power athletes. Medicine and Science in Sports and Exercise, 17, 354–359.

    PubMed  CAS  Google Scholar 

  • Allison, C. & Pratt, J. (2003). Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacology & Therapeutics, 98, 171–195.

    Article  CAS  Google Scholar 

  • American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, fourth edition, text-revision (DSM-IV-TR). Washington, D.C.: American Psychiatric Association.

  • Aragona, M. (2000). Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clinical Neuropharmacology, 23, 281–283.

    Article  PubMed  CAS  Google Scholar 

  • Arvary, D., & Pope, H. G. Jr. (2000). Anabolic steroids: a possible gateway to opioid dependence? The New England Journal of Medicine, 342, 1532.

    Article  PubMed  CAS  Google Scholar 

  • Bagatell, C. J., & Bremner, W. J. (1996). Androgens in men—uses and abuses. The New England Journal of Medicine, 334, 707–714.

    Article  PubMed  CAS  Google Scholar 

  • Bahrke, M. S., Yesalis, C. E., Kopstein A. N., & Nyberg, F. (2000). Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Medicine, 29, 397–405.

    Article  PubMed  CAS  Google Scholar 

  • Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004a). Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs, 18, 37–48.

    Article  PubMed  CAS  Google Scholar 

  • Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004b). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: A meta-analysis. Archives of Clinical Neuropsychology, 19, 437–454.

    Article  PubMed  Google Scholar 

  • Barrett, S. P., Darredeau, C., Bordy, L. E., & Pihl, R. O. (2005). Methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry, 50, 457–461.

    Google Scholar 

  • Barrett, S. P., & Pihl, R. O. (2002). Oral methylphenidate-alcohol co-abuse. Journal of Clinical Psychopharmacology, 22, 633–634.

    Article  PubMed  CAS  Google Scholar 

  • Basaria, S., Wahlstrom, J. T., & Dobs, A. S. (2001). Anabolic-androgenic steroid therapy in the treatment of chronic diseases. The Journal of Clinical Endocrinology and Metabolism, 86, 5108–5117.

    Article  PubMed  CAS  Google Scholar 

  • Bateson, A. N. (2002). Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Current Pharmaceutical Design, 8, 5–21.

    Article  PubMed  CAS  Google Scholar 

  • Batten, H. L., Prottas, J. M., Horgan, C. M., Prottas, J. M., Simon, L. J., Larson, M. J., et al. (1993). Drug services research survey. Phase II final report. Submitted to the National Institute on Drug Abuse. Waltham: Institute for Health Policy, Brandeis University.

  • Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine, 335, 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Biederman J. (2003). Pharmacology for attention deficit hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from longitudinal follow-up of youths with and without ADHD. The Journal of Clinical Psychiatry, 64(Suppl. 11), 3–8.

    PubMed  CAS  Google Scholar 

  • Biederman, J., Wilens, T., Mick, E., Milberger, S., Spencer, T. J., & Faraone, S. V. (1995). Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: Effects of ADHD and psychiatric comorbidity. The American Journal of Psychiatry, 152, 1652–1658.

    PubMed  CAS  Google Scholar 

  • Bolin, R. R. (1960). Psychiatric manifestations of Artane toxicity. The Journal of Nervous and Mental Disease, 131, 256–259.

    Article  Google Scholar 

  • Bollinger, L. C., Bush, C., Califano, J. A., Chenault, K. I., Curtis, J. L., Dimon, J., et al. (2005). Under the counter. The diversion and abuse of controlled prescription drugs in the U.S. New York: The National Center on Addiction and Substance Abuse at Columbia University (CASA).

    Google Scholar 

  • Boyd, C. J., McCabe, S. E., Cranford, J. A., & Young, A. (2006). Adolescents’ motivations to abuse prescription medications. Pediatrics, 118, 2472–2480.

    Article  PubMed  Google Scholar 

  • Bramness, J. G., Skurtveit, S., & Morland, J. (2004). Impairment due to intake of carisoprodol. Drug and Alcohol Dependence, 74, 311–318.

    Article  PubMed  CAS  Google Scholar 

  • Britt, G. C., & McCance-Katz, E. F. (2005). A brief overview of the clinical pharmacology of “club drugs.” Substance Use & Misuse, 40, 1189–1201.

    Article  Google Scholar 

  • Brower, K. J. (2000). Assessment and treatment of anabolic steroid abuse, dependence, and withdrawal. C. E. Yesalis (Ed.), Anabolic steroids in sport and exercise (2nd ed.). Champagne: Human Kinetics.

    Google Scholar 

  • Brower, K. J. (2002). Anabolic steroid abuse and dependence. Current Psychiatry Reports, 4, 377–387.

    Article  PubMed  Google Scholar 

  • Buckley, W. E., Yesalis, C. E., Friedl, K. E., Anderson, W., Streit, A. L., & Wright, J. E. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. JAMA: The Journal of the American Medical Association, 260, 3441–3445.

    Article  CAS  Google Scholar 

  • Buhrich, N., Weller, A., & Kevans, P. (2000). Misuse of anticholinergic drugs by people with serious mental illness. Psychiatric Services, 51, 928–929.

    Article  PubMed  CAS  Google Scholar 

  • Cami, J., & Farre, M. (2003). Mechanisms of disease: Drug addiction. The New England Journal of Medicine, 349, 975–986.

    Article  PubMed  CAS  Google Scholar 

  • Carlini, E. A. (1993). Preliminary note: Dangerous use of anticholinergic drugs in Brazil. Drug and Alcohol Dependence, 32, 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Challman, T. D., & Lipsky, J. J. (2000). Methylphenidate: Its pharmacology and uses. Mayo Clinic Proceedings, 75, 711–721.

    Article  PubMed  CAS  Google Scholar 

  • Choi, P. Y. L., Pope, H. G. Jr., & Olivardia, R. (2002). Muscle dysmorphia: A new syndrome in weightlifters. British Journal of Sports Medicine, 36, 375–377.

    Article  PubMed  CAS  Google Scholar 

  • Clark, H. W., & Bizzelli, A. C. (2005). A federal perspective on the abuse of prescription stimulants. Psychiatric Annals, 35, 261–263.

    Google Scholar 

  • Cohen, L. A., Jhung, M. A., & Budnitz, D. S. (2006). Stimulant medications and attention deficit-hyperactivity disorder. The New England Journal of Medicine, 354, 2294–2295.

    Article  PubMed  CAS  Google Scholar 

  • Compton, W. M., & Volkow, N. D. (2005). Abuse of prescription drugs and the risk of addiction. Drug and Alcohol Dependence, 83S, S4–S7.

    Google Scholar 

  • Congeni, J., & Millier, S. (2002). Supplements and drugs used to enhance athletic performance. Pediatric Clinics of North America, 49, 435–461.

    Article  PubMed  Google Scholar 

  • Crawshaw, J. A., & Mullen, P. E. (1984). A study of benzhexol abuse. The British Journal of Psychiatry, 145, 300–303.

    Article  PubMed  CAS  Google Scholar 

  • Crouch, B. I., Caravati, E. M., & Booth, J. (2004). Trends in child and teen nonprescription drug abuse reported to a regional poison control center. American Journal of Health-system Pharmacy, 61, 1252–1257.

    PubMed  Google Scholar 

  • Darcourt, G., Pringuey, D., Salliere, D., & Lavoisy, J. (1999). The safety and tolerability of zolpidem—an update. Journal of Psychopharmacology, 13, 81–93.

    Article  PubMed  CAS  Google Scholar 

  • DeFrates, L. J., Hoehns, J. D., Sakornbut, E. L., Glascock, D. G., & Tew, A. R. (2005). Antimuscarinic intoxication resulting from the ingestion of moonflower seeds. The Annals of Pharmacotherapy, 39, 173–176.

    PubMed  Google Scholar 

  • Fisch, R. Z. (1987). Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatrica Scandinavica, 75, 91–94.

    Article  PubMed  CAS  Google Scholar 

  • Forman, R. F., Woody, G. E., McLellan, T., & Lynch, K. G. (2006). The availability of web sites offering to sell opioid medications without prescriptions. The American Journal of Psychiatry, 163, 1233–1238.

    Article  PubMed  Google Scholar 

  • Friedman, R. A. (2006). The changing face of teenage drug abuse – the trend toward prescription drugs. The New England Journal of Medicine, 354, 1448–1450.

    Article  PubMed  CAS  Google Scholar 

  • Fryburg, D. A. (1994). Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. The American Journal of Physiology, 267, E331–E336.

    PubMed  CAS  Google Scholar 

  • Fu, C. H. Y., Abel, K. M., Allin, M. P. G., Gasston, D., Costafreda, S. G., Suckling, J., et al. (2005). Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: A functional magnetic resonance imaging study. Psychopharmacology, 183, 92–102.

    Article  PubMed  CAS  Google Scholar 

  • Garland, J. E. (1998). Intranasal abuse of prescribed methylphenidate. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 573–574.

    Article  CAS  Google Scholar 

  • Goggin, D. A., & Solomon, G. F. (1979). Trihexyphenidyl abuse for euphorigenic effect. The American Journal of Psychiatry, 136, 459–460.

    PubMed  CAS  Google Scholar 

  • Goldman, L. S., Genel, M., Bezman, R. J., & Slanetz, P. J. (1998). Diagnosis and treatment of attention deficit/hyperactivity disorder in children and adolescents. JAMA: The Journal of the American Medical Association, 279, 1100–1107.

    Article  CAS  Google Scholar 

  • Goldstein, P. (1990). Anabolic steroids: an ethnographic approach. Anabolic steroid abuse, NIDA research monograph. Rockville: NIDA.

    Google Scholar 

  • Gonzalez-Cadavid, N. F., Tayler, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K. Ezzat, S., et al (1998). Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proceedings of the National Academy of Sciences of the United States of America, 95, 14938–14943.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin, R. D., & Hasin, D. S. (2002). Sedative use and misuse in the United States. Addiction, 97, 555–562.

    Article  PubMed  Google Scholar 

  • Gopel, C., Laufer, C., & Marcus, A. (2002). Three cases of angel’s trumpet tea-induced psychosis in adolescent substance abusers. Nordic Journal of Psychiatry, 56, 49–52.

    Article  PubMed  Google Scholar 

  • Greenhill, L. (2005). The science of stimulant abuse. Psychiatric Annals, 35, 210–214.

    Google Scholar 

  • Gurley, R. J., Aranow, R., & Katz, M. (1998). Medicinal marijuana: A comprehensive review. Journal of Psychoactive Drugs, 30, 137–147.

    PubMed  CAS  Google Scholar 

  • Hadidi, K. A. (2004). Development of a screening method for the most commonly abused anticholinergic drugs in Jordan; trihexyphenidyl, procyclidine, and biperiden. Legal Medicine (Tokyo, Japan), 6, 233–241.

    CAS  Google Scholar 

  • Hajak, G., Muller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction, 98, 1371–1378.

    Article  PubMed  CAS  Google Scholar 

  • Hemmelgarn, B., Suissa, S., Huang, A., Boivin, J. F., & Pinard, G. (1997). Benzodiazepine use and the risk of motor vehicle crash in the elderly. Journal of the American Medical Association, 278, 27–31.

    Article  PubMed  CAS  Google Scholar 

  • Hickson, R. C., Czerwinski, S. M., Falduto, M. T., & Young, A. P. (1990). Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Medicine and Science in Sports and Exercise, 22, 331–340.

    PubMed  CAS  Google Scholar 

  • Huang, B., Dawson, D. A., Stinson, F. S., Hasin, D. S., Ruan, W. J., Saha, T. D., et al. (2006). Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiological Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 1062–1073.

    Article  PubMed  Google Scholar 

  • Hussain, M. Z., Waheed, W., & Hussain, S. (2005). Intravenous quetiapine abuse. The American Journal of Psychiatry, 162, 1755–1756.

    Article  PubMed  CAS  Google Scholar 

  • Hutchinson, M. A., Smith, P. F., & Darlington, C. L. (1996). The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Progress in Neurobiology, 49, 73–97.

    PubMed  CAS  Google Scholar 

  • Isaacson, J. H., Hopper, J. A., Alford, D. P., & Parran, T. (2005). Prescription drug use and abuse. Risk factors, red flags, and prevention strategies. Postgraduate Medicine, 118, 19–26.

    Article  PubMed  Google Scholar 

  • Isbister, G. K., Oakley, P., Dawson, A. H., & Whyte, I. M. (2003). Presumed Angel’s trumpet (Brugmansia) poisoning: Clinical effects and epidemiology. Emergency Medicine (Fremantle, W.A.), 15, 376–382.

    Article  Google Scholar 

  • Jadad, A. R., Boyle, M., Cunningham, C., Kim, M., & Schachar, R. (1999). Treatment of attention deficit hyperactivity disorder. Agency for Healthcare Research and Quality, US Department of Health and Human Services. Retrieved March 30, 2007, from http://www.ncbi.nih.gov/books/bv.fcgi?rid=hstat1.chapter.14677.

  • Jellinek, T. (1977). Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Diseases of the Nervous System, 38, 353–355.

    PubMed  CAS  Google Scholar 

  • Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2005). Monitoring the future national survey results on drug use, 1975–2004, vol. I: Secondary school students. Bethesda: National Institute on Drug Abuse.

    Google Scholar 

  • Kanayama, G., Barry, S., Hudson, J. I., & Pope, H. G. Jr. (2006). Body image and attitudes toward male roles in anabolic-androgenic steroid users. The American Journal of Psychiatry, 63, 697–703.

    Article  Google Scholar 

  • Kanayama, G., Pope, H. G. Jr., Cohane, G., & Hudson, J. I. (2003). Risk factors for anabolic-androgenic steroid use among weightlifters: A case-control study. Drug and Alcohol Dependence, 71, 77–86.

    Article  PubMed  Google Scholar 

  • Kanayama, G., Pope, H.G. Jr., & Hudson, J. I. (2001). “Body image” drugs: A growing psychosomatic problem. Psychotherapy and Psychosomatics, 70, 61–65.

    Article  PubMed  CAS  Google Scholar 

  • Kaminer, Y., Munitz, H., & Wijsenbeek, H. (1982). Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. The British Journal of Psychiatry, 140, 473–474.

    Article  PubMed  CAS  Google Scholar 

  • Katzung, B. G. (1986). Basic and clinical pharmacology. Norwalk: Lange Medical Publications.

    Google Scholar 

  • Katzung, B. G. & Trevor, A. J. (1998). Sedative-hypnotic drugs. In Examination and board review pharmacology (pp. 171–178). New York: McGraw-Hill.

    Google Scholar 

  • Kouri, E., Lukas, S. E., Pope, H. G. Jr, & Oliva, P. S. (1995). Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug and Alcohol Dependence, 40, 73–79.

    Article  PubMed  CAS  Google Scholar 

  • Kouri, E., Pope, H. G. Jr, Katz, D. L., & Oliva, P. (1995). Fat-free mass index in users and non-users of anabolic-androgenic steroids. Clinical Journal of Sport Medicine, 5, 223–228.

    Article  PubMed  CAS  Google Scholar 

  • Kripke, D. F., Klauber, M. R., Wingard, D. I., & Fell, R. L. (1998). Mortality hazards associated with prescription of hypnotics. Biological Psychiatry, 43, 687–693.

    Article  PubMed  CAS  Google Scholar 

  • Kroutil, L. A., Van Brunt, D. L., & Herman-Stahl, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence, 84, 135–143.

    Article  PubMed  Google Scholar 

  • Krystal, J. H., Staley, J., Mason, G., Petrakis, I. L., Kaufman, J., Harris, R. A., et al. (2006). Gamma-aminobutyric acid type A receptors and alcoholism: Intoxication, dependence, vulnerability, and treatment. Archives of General Psychiatry, 63, 957–968.

    Article  PubMed  CAS  Google Scholar 

  • Land, W., Pinsky, D., & Salzman, C. (1991). Abuse and misuse of anticholinergic medications. Hospital & Community Psychiatry, 42, 580–581.

    CAS  Google Scholar 

  • Lowry, T. P. (1977). Trihexyphenidyl abuse. The American Journal of Psychiatry, 134, 1315.

    Google Scholar 

  • Malcolm, R. J. (2003). GABA systems, benzodiazepines, and substance dependence. The Journal of Clinical Psychiatry, 64, 36–40.

    PubMed  CAS  Google Scholar 

  • Malone, D. A. Jr., & Dimeff, R. J. (1992). The use of fluoxetine in depression associated with anabolic steroid withdrawal: A case series. The Journal of Clinical Psychiatry, 53, 130–132.

    PubMed  Google Scholar 

  • Malone, D. A. Jr., Dimeff, R. J., & Lombardo, J. A. (1995). Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid abusers. Clinical Journal of Sport Medicine, 5, 223–228.

    Article  Google Scholar 

  • Manchikanti, L. (2006). Prescription drug abuse: What is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources. Pain Physician, 9, 287–321.

    PubMed  Google Scholar 

  • Manchikanti, L., Whitfield, E., & Pallone, F. (2005). Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): A public law for balancing treatment of pain and drug abuse and diversion. Pain Physician, 8, 335–347.

    PubMed  Google Scholar 

  • Markowitz, J. S., Logan, B. K., Diamond, F., & Patrick, K. S. (1999). Detection of a novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. Journal of Clinical Psychopharmacolology, 19, 362–366.

    Article  CAS  Google Scholar 

  • Marriott, P. (1976). Dependence on antiparkinsonian drugs. British Medical Journal, 1(6002), 152.

    Article  PubMed  CAS  Google Scholar 

  • Matochik, J., Nordahl, T., & Gross, M. (1993). Effects of acute stimulant medication on cerebral metabolism on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology, 8, 377–386.

    PubMed  CAS  Google Scholar 

  • Maxwell, C. R., Ehrlichman, R. S., Liang, Y, Trief, D., Kanes, S. J., Karp, J., et al. (2006). Ketamine produces lasting disruptions in encoding of sensory stimuli. The Journal of Pharmacology and Experimental Therapeutics, 316, 315–324.

    Article  PubMed  CAS  Google Scholar 

  • McCabe, S. E., Knight J. R., Teter, C. J., & Weschler, H. (2005). Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction, 99, 96–106.

    Article  Google Scholar 

  • McCabe, S. E., Teter, C. J., & Boyd, C. J. (2004). The use, misuse a new version of prescription stimulants among middle and high school students. Substance Use and Misuse, 39, 1095–1117.

    Article  PubMed  Google Scholar 

  • McCabe, S. E., Teter, C. J., & Boyd, C. J. (2006). Medical use, illicit use, and diversion of abusable prescription drugs. Journal of American College Health, 54, 269–278.

    Article  PubMed  Google Scholar 

  • McInnis, M., & Petursson, H. (1984). Trihexyphenidyl dependence. Acta Psychiatrica Scandinavica, 69, 538–542.

    Article  CAS  Google Scholar 

  • McInnis, M., & Petursson, H. (1985). Withdrawal of trihexyphenidyl. Acta Psychiatrica Scandinavica, 71, 297–303.

    Article  PubMed  CAS  Google Scholar 

  • Melia, P., Pipe, A., & Greenberg, L. (1996). The use of anabolic-androgenic steroids by Canadian students. Clinical Journal of Sport Medicine, 6, 9–14.

    Article  PubMed  CAS  Google Scholar 

  • Monitoring the Future (2003). Data from in school surveys of eighth, 10th, and 12th grade students. Drug and alcohol press release: Trends in use of various drugs. Retrieved on March 30, 2007, from http://www.monitoringthefuture.org/data/03data/pr03t1.pdf.

  • Morgan, W. W. (1990). Abuse liability of barbiturates and other sedative-hypnotics. Advances in Alcohol and Substance Abuse, 9, 67–82.

    PubMed  CAS  Google Scholar 

  • Morgan, C. J. A., & Curran H. V. (2006). Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology, 188, 408–424.

    Article  PubMed  CAS  Google Scholar 

  • Morin, C. M., Bastien, C., Guay, B., Radouco-Thomas, M., Leblanc, J., & Vallieres, A. (2004). Randomized clinical trial of supervised tapering and cognitive behavioral therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. The American Journal of Psychiatry, 161, 332–342.

    Article  PubMed  Google Scholar 

  • Morris, M. C., Cline R. J., Weiler R. M., & Broadway S. C. (2006). Prescription drug abuse information in D.A.R.E. Journal of Drug Education, 36, 33–45.

    Article  PubMed  Google Scholar 

  • Nappo, S. A., de Oliveira, L. G., Sanchez, Z. M., & Carlini, E. A. (2005). Trihexyphenidyl (Artane): A Brazilian study of its abuse. Substance Use & Misuse, 40, 473–482.

    Article  Google Scholar 

  • Narendran, R., Frankle, W. G., Keefe, R., Gil, R., Martinez, D., Slifstein, M., et al. (2005). Altered prefrontal dopaminergic function in chronic recreational ketamine users. The American Journal of Psychiatry, 162, 2352–2359.

    Article  PubMed  Google Scholar 

  • O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence. The Journal of Clinical Psychiatry, 66, 28–33.

    Article  PubMed  CAS  Google Scholar 

  • Olfson, M., Gameroff, M. J., Marcus, S. C., & Jensen, P. S. (2003). National trends in the treatment of attention deficit hyperactivity disorder. The American Journal of Psychiatry, 160, 1071–1077.

    Article  PubMed  Google Scholar 

  • Olivardia, R., Pope, H. G., & Hudson, J. I . (2000). Muscle dysmorphia in male weightlifters: A case-control study. The American Journal of Psychiatry, 157, 1291–1296.

    Article  PubMed  CAS  Google Scholar 

  • Oude Voshaar, R. C., Couvee, J. E., Van Balkom, A. J., Mulder, P. G., & Zitman, F. G. (2006). Strategies for discontinuing long-term benzodiazepine use: Meta-analysis. The British Journal of Psychiatry, 189, 213–220.

    Article  Google Scholar 

  • Parrott, A. C., Choi, P. Y. L., & Davies, M. (1994). Anabolic steroid use by amateur athletes: Effects upon psychological mood states. The Journal of Sports Medicine and Physical Fitness, 34, 292–298.

    PubMed  CAS  Google Scholar 

  • Pierre, J. M., Shnayder, I., Wirshing, D. A., & Wirshing, W. C. (2004). Intranasal quetiapine abuse. The American Journal of Psychiatry, 161, 1718.

    Article  PubMed  Google Scholar 

  • Pinta, E. R., & Taylor, R. E. (2007). Quetiapine addiction? The American Journal of Psychiatry, 164, 174.

    Article  PubMed  Google Scholar 

  • Pittinger, C., & Desan, P. H. (2007). Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. The Journal of Clinical Psychiatry, 68, 483–484.

    Article  Google Scholar 

  • Pope, H. G. Jr & Brower, K. J. (2004). Anabolic-androgenic steroids. In Textbook of substance abuse treatment (3rd ed.). Washington, D.C.: American Psychiatric Publishing Inc.

    Google Scholar 

  • Pope, H. G. Jr., & Katz, D. L. (1994). Psychiatric and medical effects of anabolic-androgenic steroid abuse: a controlled study of 160 athletes. Archives of General Psychiatry, 51, 375–382.

    PubMed  CAS  Google Scholar 

  • Pope, H. G. Jr., & Katz, D. L. (2003). Psychiatric effects of exogenous anabolic-androgenic steroids. In Psychoneuroendocrinology. Washington, D.C.: American Psychiatric Publishing, Inc.

    Google Scholar 

  • Pope, H. G. Jr., Kouri, E., & Hudson, J. I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Archives of General Psychiatry, 57, 133–140.

    Article  PubMed  CAS  Google Scholar 

  • Porcerelli, J. H., & Sandler, B. A. (1998). Anabolic-androgenic steroid abuse and psychopathology. The Psychiatric Clinics of North America, 21, 829–833.

    Article  PubMed  CAS  Google Scholar 

  • Rabkin, J. G., Wagner, G. J., & Rabkin, R. (2000). A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry, 57, 141–147.

    Article  PubMed  CAS  Google Scholar 

  • Ravishankar, A., & Carnwath, T. (1998). Zolpidem tolerance and dependence—two case reports. Journal of Psychopharmacology, 12, 103–104.

    Article  PubMed  CAS  Google Scholar 

  • Ray, W. A., Griffin, M. R., Schaffner, W., Bauth, D. K., & Melton, L. J. (1987). Psychotropic drug use and the risk of hip fracture. The New England Journal of Medicine, 316, 363–369.

    Article  PubMed  CAS  Google Scholar 

  • Reeves, R. R., Carter, O. S., Pinkofsky, H. B., Struve, F. A., & Bennett, D. M. (1999). Carisoprodol (Soma): Abuse potential and physician unawareness. Journal of Addictive Diseases, 18, 51–56.

    Article  PubMed  CAS  Google Scholar 

  • Robins, L. N., & Regier, D. A. (Eds.) (1991). Psychiatric disorders in America. New York: The Free Press.

  • Rouchell, A. M., & Dixon S. P. (1977). Trihexyphenidyl abuse. The American Journal of Psychiatry, 134, 1315.

    Google Scholar 

  • Rubinstein, J. S. (1978). Abuse of antiparkinsonism drugs: feigning of extrapyramidal symptoms to obtain trihexyphenidyl. JAMA: The Journal of the American Medical Association, 239, 2365–2366.

    Article  CAS  Google Scholar 

  • Rubinstein, J. S. (1978). Abuse of anticholinergic drugs. The New England Journal of Medicine, 299, 834.

    PubMed  CAS  Google Scholar 

  • Rush, C. R., Baker, R. W., & Wright, K. (1999). Acute behavioral effects and abuse potential of trazodone, zolpidem, and triazolam in humans. Psychopharmacology, 144, 220–233.

    Article  PubMed  CAS  Google Scholar 

  • Rust, G. S., Hatch, R., & Gums, J. G. (1993). Carisoprodol as a drug of abuse. Archives of Family Medicine, 2, 429–432.

    Article  PubMed  CAS  Google Scholar 

  • Sareen, J., Enns, M. W., & Cox, B. J. (2004). Potential for misuse of sedatives. The American Journal of Psychiatry, 161, 1723.

    Article  Google Scholar 

  • Sattar, S. P., Bhatia, S. C., & Petty, F. (2004). Potential benefits of quetiapine in the treatment of substance dependence disorders. Journal of Psychiatry and Neuroscience, 29, 452–457.

    PubMed  Google Scholar 

  • Schuster, C. R. (2006). History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug and Alcohol Dependence, 83S, S8–S14.

    Article  CAS  Google Scholar 

  • Sessa, B. (2007). Is there a case for MDMA-assisted psychotherapy in the UK? Journal of Psychopharmacology, 21, 220–224.

    Article  PubMed  CAS  Google Scholar 

  • Simoni-Wastila, L., & Yang, H. K. (2006). Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy, 4, 380–394.

    Article  PubMed  Google Scholar 

  • Smith, J. M. (1980). Abuse of the antiparkinson drugs: a review of the literature. The Journal of Clinical Psychiatry, 41, 351–354.

    PubMed  CAS  Google Scholar 

  • Smith, M. (2006). Cardiovascular safety warning added for stimulants ffor ADHD. Retrieved March 26, 2007, from http://www.medpagetoday.com/ProductAlert/Prescriptions/tb2/3987.

  • Soyka, M., Bottlender, R., & Moller, H. J. (2000). Epidemiological evidence for low abuse potential of zolpidem. Pharmacopsychiatry, 33, 138–141.

    Article  PubMed  CAS  Google Scholar 

  • Stern, T. A. (1983). Continuous infusion of physostigmine in anticholinergic delirium: Case report. The Journal of Clinical Psychiatry, 44, 463–464.

    PubMed  CAS  Google Scholar 

  • Stewart, S. A. (2005). The effects of benzodiazepines on cognition. The Journal of Clinical Psychiatry, 66, 9–13.

    Article  PubMed  CAS  Google Scholar 

  • Stilger, V. G., & Yesalis, C. E. (1999). Anabolic-androgenic steroid use among high school football players. Journal of Community Health, 24, 131–145

    Article  PubMed  CAS  Google Scholar 

  • Su, T.-P., Pagliaro, M., & Schmidt, P. J. (1993). Neuropsychiatric effects of anabolic steroid in male normal volunteers. JAMA: The Journal of the American Medical Association, 269, 2760–2764.

    Article  CAS  Google Scholar 

  • Substance Abuse and Mental Health Services Administration (2003). Results from the 2002 national survey on drug use and health: National findings (NSDUH Series H-22, DHHS publication no. sma 03–3836). Rockville: Office of Applied Sciences.

    Google Scholar 

  • Taylor, S., McCracken, C. F., Wilson, J. C., & Copeland, J. R. (1998). Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. The British Journal of Psychiatry, 173, 433–438.

    Article  PubMed  CAS  Google Scholar 

  • Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26, 1501–1510.

    Article  PubMed  Google Scholar 

  • Tincello, D. G., Saunders, P. T., Hodgins, M. B., Simpson, N. B., Edwards, C. R., Hargreaves, T. B., et al. (1997). Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone therapy in patients with partial androgen insensitivity syndrome. Clinical Endocrinology, 46, 497–506.

    Article  PubMed  CAS  Google Scholar 

  • Tokish, J. M., Kocher, M. S., & Hawkins, R. J. (2004). Ergogenic aids: a review of basic science, performance, side effects, and status in sports. The American Journal of Sports Medicine, 32, 543–1553.

    Article  Google Scholar 

  • Tso, M. M., Blatchford, K. L., Callado, L. F., McLaughlin, D. P., & Stamford, J. A. (2004). Stereoselective effects of ketamine on dopamine, serotonin, and noradrenaline release and uptake in rat brain slices. Neurochemistry International, 44, 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Victorri-Vigneau, C., Guerlais, M., & Jolliet, P. (2007). Abuse, dependency and withdrawal with gabapentin: A first case report. Pharmacopsychiatry, 40, 43–44.

    Article  PubMed  CAS  Google Scholar 

  • Volkow, N. D. (2006). Stimulant medications: how to minimize their reinforcing effects? The American Journal of Psychiatry, 163, 387–395.

    Article  Google Scholar 

  • Volkow, N. D., & Swanson, J. M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. The American Journal of Psychiatry, 160, 1909–1918.

    Article  PubMed  Google Scholar 

  • Voshaar, R. C., Gorgels, W. J., Mol, A. J., van Balkom, A. J., Mulder, J., van de Lisdonk, E. H., et al. (2006). Predictors of long-term benzodiazepine abstinence in participants of a randomized-controlled benzodiazepine withdrawal program. Canadian Journal of Psychiatry, 51, 445–452.

    Google Scholar 

  • Warner, L. A., Kessler, R. C., Hughes, M., Anthony, J. C., & Nelson, C. B. (1995). Prevalences and correlated of drug use and dependences in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 52, 219–229.

    PubMed  CAS  Google Scholar 

  • Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179–185.

    Article  PubMed  Google Scholar 

  • Wills, S. (2005). Drugs of abuse. London: Pharmaceutical Press.

    Google Scholar 

  • Wines, J. D. Jr., Gruber, A. J., Pope, H. G. Jr., & Lukas, S. E. (1999). Nalbuphine hydrochloride dependence in anabolic steroid users. The American Journal on Addictions, 8, 161–164.

    Article  PubMed  Google Scholar 

  • Wood, R. I. (2004). Reinforcing aspects of androgens. Physiology and Behavior, 83, 279–289.

    PubMed  CAS  Google Scholar 

  • Wu, F. C. (1997). Endocrine aspects of anabolic steroids. Clinical Chemistry, 43, 289–1292.

    Google Scholar 

  • Yates, W. R., Perry, P., MacIndoe, J., Holman, T., & Ellingrod, V. (1999). Psychosexual effects of three doses of testosterone cycling in normal men. Biological Psychiatry, 45, 254–260.

    Article  PubMed  CAS  Google Scholar 

  • Yesalis, C. E. (1992). Epidemiology and patterns of anabolic-androgenic steroid use. Psychiatric Annals, 22, 7–18.

    Google Scholar 

  • Zametkin, A. J., Nordahl, T. E., Gross M., King, A. C., Semple, W. E., Rumsey, J., et al. (1990). Cerebral glucose metabolism in adults with hyperactivity of childhood onset. The New England Journal of Medicine, 323, 1361–1366.

    Article  PubMed  CAS  Google Scholar 

  • Zarocostas, J. (2007). Misuse of prescription drugs could soon exceed that of illicit narcotics, UN panel warns. British Medical Journal, 334, 334.

    Google Scholar 

  • Zawertailo, L. A., Busto, U. E., Kaplan, H. L., Greenblatt, D. J, & Sellers, E. M. (2003). Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. Journal of Clinical Psychopharmacology, 23, 269–280.

    Article  PubMed  CAS  Google Scholar 

  • Zemishlany, Z., Aizenberg, D., Weiner, Z., & Weizman, A. (1996). Trihexyphenidyl (Artane) abuse in schizophrenic patients. International Clinical Psychopharmacology, 11, 199–202.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jason P. Caplan.

Appendices

Appendix

DSM-IV Diagnostic Criteria for Substance Abuse/Dependence

Substance Abuse

Substance use resulting in significant impairment or distress, as manifested by at least one of the following, within a 12-month period:

  1. 1.

    recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences or poor work performance; absences, suspensions, or expulsions from school; neglect of children or household)

  2. 2.

    recurrent substance use in physically hazardous situations (e.g., driving while intoxicated)

  3. 3.

    recurrent substance-related legal problems

  4. 4.

    continued substance use despite persistent social or relational problems (e.g., arguments with spouse, physical fights)

The symptoms have never met the criteria for Substance Dependence for this class of substance.

Substance Dependence

Substance use, resulting in significant impairment or distress, as manifested by at least three of the following, occurring at any time in the same 12-month period:

  1. 1.Tolerance,

    as demonstrated by:

    1. (a)

      a requirement for increased amounts of the substance to achieve intoxication or desired effect

    2. (b)

      diminished effect with continued use of the same amount of the substance

  2. 2.

    Withdrawal, as demonstrated by either of the following:

    1. (a)

      the characteristic withdrawal syndrome for the substance

    2. (b)

      the substance, or a similar substance, is taken to relieve or avoid withdrawal symptoms

  3. 3.

    The substance is used in larger amounts or over a longer period than intended

  4. 4.

    A persistent desire or unsuccessful efforts to diminish or control substance use

  5. 5.

    Significant time is spent in activities necessary to obtain the substance (e.g., visiting multiple doctors, driving long distances), use the substance, or recover from its effects

  6. 6.

    Important social, occupational, or recreational activities are reduced or discontinued because of substance use

  7. 7.

    Substance use is continued despite knowledge of a physical or psychological problem that is likely to have been caused or exacerbated by the substance

Adapted from: Diagnostic and statistical manual of mental disorders, fourth edition, text-revision (DSM-IV-TR). (2000). Washington, D.C.: American Psychiatric Association.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caplan, J.P., Epstein, L.A., Quinn, D.K. et al. Neuropsychiatric Effects of Prescription Drug Abuse. Neuropsychol Rev 17, 363–380 (2007). https://doi.org/10.1007/s11065-007-9037-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11065-007-9037-7

Keywords

Navigation